Valeant Pharmaceuticals Intl. Inc.'s Biggest Catalysts in 2017

Valeant Pharmaceuticals Intl. Inc.'s Biggest Catalysts in 2017


However, despite its well-documented struggles, Valeant is also incredibly inexpensive, assuming the company can hit a profit forecast that's been lowered three times for fiscal 2016. Based on its most recent update during the third quarter, Valeant is on track to produce $5.40 in full-year earnings per share at the midpoint and $4.3 billion in EBITDA at the midpoint.



from Biotech News